OncologyGold rushData as of 2026-09-04
Ovarian Cancer is both crowded and richly priced: 9 companies are in the clinic and the median one is worth $1.4B, against a universe median of $1.20B.
Crowded fields usually trade at a discount per company, so a premium in a field this deep says the market is pricing the size of the prize above the cost of the competition.
3 of the 9 are in Phase 3 or filed, and 7 dated catalysts fall in the next 12 months, so this ranking is likely to move.
$6.7B of allocated capital sits in Ovarian Cancer, ranking it 29th of 299 indications by the money committed to it.
| Ticker | Company | Lead asset | Phase | Trials | Market cap | Pure play | Indications | Next catalyst |
|---|---|---|---|---|---|---|---|---|
| CORT | Corcept Therapeutics | Relacorilant once daily | Phase 3 | 2 | $12.2B | No | 3 | 31 Dec 2026 |
| ZNTL | Zentalis Pharmaceuticals | Azenosertib | Phase 3 | 2 | $295M | No | 3 | 23 Oct 2026 |
| GNLX | Genelux | Olvimulogene nanivacirepvec | Phase 3 | 3 | $113M | No | 3 | 31 Dec 2026 |
| IBRX | ImmunityBio | M-CENK, for Infusion, Cryopreserved | Phase 2 | 2 | $8.7B | No | 12 | 31 Dec 2026 |
| XNCR | Xencor | vudalimab | Phase 2 | 4 | $2.0B | No | 4 | 23 Oct 2026 |
| MGNX | MacroGenics | Lorigerlimab | Phase 2 | 1 | $270M | No | 3 | 30 Sep 2026 |
| PGEN | Precigen | PRGN-3005 UltraCAR-T cells | Phase 1 | 1 | $2.5B | No | 3 | No dated event |
| AVBP | ArriVent BioPharma | ARR-002 | Phase 1 | 1 | $1.4B | No | 5 | No dated event |
| DTIL | Precision BioSciences | CD70 CAR-T cells | Phase 1 | 1 | $203M | No | 16 | 31 Dec 2026 |
Sorted by phase, then by market capitalisation. Ticker links open the company profile. CORT holds 44% of the $27.7B competing in this indication.
Crowded and richly priced: six or more competitors, and the median one is worth more than the median small or mid cap biotech.
Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.
See every Oncology indication on the map9 US-listed companies in the $100M to $20B market cap band run clinical programmes in Ovarian Cancer. The largest and most advanced are Corcept Therapeutics (CORT, Relacorilant once daily, Phase 3); Zentalis Pharmaceuticals (ZNTL, Azenosertib, Phase 3); Genelux (GNLX, Olvimulogene nanivacirepvec, Phase 3); ImmunityBio (IBRX, M-CENK, for Infusion, Cryopreserved, Phase 2); Xencor (XNCR, vudalimab, Phase 2). The full list of 9 is in the table on this page.
Of the 9 clinical-stage programmes in Ovarian Cancer, 3 are in Phase 3 or filed, 3 are in mid-stage development and 3 are in early-stage development.
The median company developing a drug for Ovarian Cancer is worth $1.4B, against a median of $1.20B across the whole universe. $6.7B of allocated capital sits in the indication, ranking it 29th of 299.
The next dated catalyst in Ovarian Cancer is MGNX on 30 Sep 2026. 7 dated events across the field fall in the next 12 months.
Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.
Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.
Back to the disease map